Identification of antiviral compounds against equid herpesvirus-1 using RTCA screening

Côme Thieulent (1, 2) , Stéphane Pronost (1, 2) , Gabrielle Sutton (1, 2)

1 LABÉO - LABÉO, Pôle d’analyses et de recherche de Normandie
2 BIOTARGEN - Biologie, génétique et thérapies ostéoarticulaires et respiratoires

Equid alpha-herpesviruses (EHV) are responsible for different diseases in equine population. EHV-1 causes respiratory diseases, abortions and nervous disorders, In this presentation, we documented the interest of the Real-Time Cell Analysis (RTCA) technology to monitor the cytopathic effects induced by EHV-1 on equine dermal cells, and established the efficacy of this method to evaluate the antiviral effect of aciclovir and ganciclovir . In addition, the RTCA technology has also been found appropriate for the high-throughput screening of small molecules against EHV. Among the 2891 compounds screened, 22 molecules have been found to be effective in vitro against EHV-1. Decitabine, ganciclovir, and valganciclovir, were the most effective compounds identified, and their antiviral potency was further assessed on E. Derm, RK13 and EEK cells and against 3 different field strains of EHV-1 (ORF30 2254A/G/C) using RTCA technology. We also provide evidences of synergistic interactions between valganciclovir and decitabine in our in vitro antiviral assay as determined by impedance measurement and qPCR assays. (https://www.youtube.com/watch?v=haM3ThKw6GU)

Mots clés: EHV-1; Antiviral

Domaines: Médecine vétérinaire et santé animale

Côme Thieulent, Stéphane Pronost, Gabrielle Sutton. Identification of antiviral compounds against equid herpesvirus-1 using RTCA screening. Labroots, Oct 2020, Caen, France. ⟨hal-03219293⟩